hemophilia

Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing
Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing
Fierce Pharma
Roche
Hemlibra
hemophilia
FDA
breakthrough status
ICER
Flag link:
Novo charts course for sickle cell amid headwinds in hemophilia
Novo charts course for sickle cell amid headwinds in hemophilia
Biopharma Dive
Novo Nordisk
sickle cell disease
hemophilia
EPI01
EpiDestiny
Flag link:
Under fire for 5 deaths of patients taking Hemlibra, Roche spills details
Under fire for 5 deaths of patients taking Hemlibra, Roche spills details
Fierce Pharma
Hemlibra
Roche
hemophilia
Flag link:
Hemophilia groups warned of 5 deaths among patients taking Roche’s big new blockbuster Hemlibra
Hemophilia groups warned of 5 deaths among patients taking Roche’s big new blockbuster Hemlibra
Endpoints
hemophilia
Roche
Hemlibra
Flag link:
Sanofi Leads the Hemophilia Space on Bioverativ Acquisition
Sanofi Leads the Hemophilia Space on Bioverativ Acquisition
Market Realist
Sanofi
hemophilia
Bioverativ
M&A
Flag link:
Sanofi to Buy Biogen Hemophilia Spinoff for $11.6 Billion
Sanofi to Buy Biogen Hemophilia Spinoff for $11.6 Billion
Bloomberg
Sanofi
M&A
Bioverativ
Biogen
hemophilia
Flag link:
Shire's latest approval won't save it from Hemlibra
Shire's latest approval won't save it from Hemlibra
Biopharma Dive
Shire
Hemlibra
Adynovi
hemophilia
Europe
Adynovate
Flag link:
Shire looks to stall Hemlibra impact with court injunction
Shire looks to stall Hemlibra impact with court injunction
BioPharma Dive
Shire
Hemlibra
Roche
hemophilia
Flag link:
Alnylam, Sanofi given the all-clear to resume fitusiran trials
Alnylam, Sanofi given the all-clear to resume fitusiran trials
BioPharma Dive
Alnylam
Sanofi
clinical trials
fitusiran
hemophilia
Flag link:
Shire CEO: Hemophilia will remain a core business
Shire CEO: Hemophilia will remain a core business
BioPharma Dive
Shire
Pharma CEOs
hemophilia
Flemming Ornskov
Flag link:
Disruption of the Year: Long-Acting Hemophilia Drugs
Disruption of the Year: Long-Acting Hemophilia Drugs
BioPharma Dive
hemophilia
Eloctate
Kovaltry
Bayer
Bioverativ
Flag link:
Startup seeking to resurrect Vioxx, arthritis drug pulled from market
Startup seeking to resurrect Vioxx, arthritis drug pulled from market
Stat
Vioxx
Merck
hemophilia
Tremeau Pharmaceuticals
Flag link:
On Eve of Big Data Reveal, Patient Death Stalls Alnylam Hemophilia Drug
On Eve of Big Data Reveal, Patient Death Stalls Alnylam Hemophilia Drug
Xconomy
Alnylam
fitusiran
hemophilia
Flag link:
Bioverativ and Bicycle keep rare disease deals rolling
Bioverativ and Bicycle keep rare disease deals rolling
BioPharma Dive
Bioverativ
Bicycle Therapeutics
R&D
drug development
sickle cell disease
hemophilia
Flag link:
Pfizer puts hemophilia spin on ultrapopular Minecraft to educate young patients
Pfizer puts hemophilia spin on ultrapopular Minecraft to educate young patients
Fierce Pharma
Pfizer
hemophilia
patients
Flag link:
BioMarin, Spark, raising the stakes for hemophilia
BioMarin, Spark, raising the stakes for hemophilia
BioPharma Dive
Biomarin
Spark Therapeutics
hemophilia
BMN 270
SPK-9001
gene therapy
Flag link:
Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab
Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab
Motley Fool
Shire
Roche
hemophilia
emicizumab
Flag link:
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Endpoints
Sanofi
Alnylam
clinical trials
fitusiran
hemophilia
Roche
emicizumab
Flag link:
Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal
Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal
Endpoints
Pfizer
gene therapy
hemophilia
Sangamo BioSciences
SB-525
hemophilia A
Flag link:
Roche confirms patient death in ACE910 PhIII hemophilia trial, spurring new questions about top blockbuster hopeful
Roche confirms patient death in ACE910 PhIII hemophilia trial, spurring new questions about top blockbuster hopeful
Endpoints
Roche
ACE910
hemophilia
clinical trials
Flag link:

Pages